Kallyope Reports Promising Phase 2b Results for Elismetrep, Introducing a Novel Mechanism for Acute Migraine Treatment
Kallyope, a late-stage biotechnology company dedicated to developing innovative therapies for neurological and metabolic disorders, has announced encouraging results from its Phase 2b clinical study of elismetrep, an investigational treatment for acute migraine. The findings were presented at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago, highlighting a potential new therapeutic pathway for millions of patients affected by migraine worldwide.
Migraine remains one of the most prevalent and disabling neurological disorders globally, characterized by severe, recurring headaches often accompanied by nausea, light sensitivity, and other debilitating symptoms. Despite the availability of multiple treatment options, a significant proportion of patients continue to experience inadequate relief, underscoring the urgent need for novel approaches. Elismetrep represents a promising candidate in this space, offering a first-in-class mechanism targeting the TRPM8 migraine-associated channel.
A Novel Mechanism: TRPM8 Channel Blockade
Elismetrep is designed as a TRPM8 (Transient Receptor Potential Melastatin 8) channel blocker, a novel mechanism of action not previously exploited in migraine treatment. TRPM8 is a sensory receptor involved in detecting cold stimuli and has recently been implicated in migraine pathophysiology. By blocking this channel, elismetrep aims to interrupt the cascade of neurological signals associated with migraine attacks.
This innovative approach sets elismetrep apart from currently available therapies such as triptans, CGRP inhibitors, and other acute treatments, which primarily target vascular or neuropeptide pathways. The development of TRPM8 migraine-associated channel blockers (MACBs) could potentially redefine how migraine is treated, particularly for patients who do not respond well to existing medications.
Study Design and Methodology
The Phase 2b study was a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of elismetrep across multiple dose levels. The study enrolled 431 participants who experienced between 2 and 10 migraine attacks per month.
Participants were randomized into treatment groups receiving either placebo or one of four doses of elismetrep: 2 mg, 5 mg, 10 mg, or 20 mg. The allocation followed a 2:1:2:2:1 ratio, ensuring a balanced distribution across treatment arms. Importantly, the study accounted for variability in patient profiles by stratifying participants based on their use of preventive migraine therapies.
Each participant was instructed to treat a single migraine attack of moderate to severe intensity. Data collection relied heavily on real-time patient-reported outcomes באמצעות an electronic diary (e-Diary), ensuring accurate and timely recording of symptoms and treatment responses.
Key Endpoints and Evaluation Criteria
The study focused on several clinically meaningful endpoints assessed at the two-hour mark following treatment administration:
- Primary Endpoint: Pain freedom at 2 hours
- Secondary Endpoints:
- Freedom from the most bothersome symptom (MBS)
- Pain relief at 2 hours
To ensure robust data analysis, the study incorporated both primary e-Diary data and a supplementary dataset (“All Data”) that included follow-up interviews for participants who missed e-Diary entries.
Participant Demographics
Out of the 431 participants enrolled, 398 treated a qualifying migraine attack and were included in the efficacy analysis. The study population had the following characteristics:
- Mean age: 46 years
- Gender distribution: 87% female
- 35% were using preventive migraine therapies
- 31% were resistant to triptan treatments
This diverse patient population reflects real-world clinical scenarios, enhancing the relevance of the study findings.
Efficacy Results
The results demonstrated that elismetrep produced dose-dependent and time-dependent improvements in migraine symptoms, with the 20 mg dose showing the most pronounced benefits.
Pain Freedom at 2 Hours
- Elismetrep 20 mg:
- 17.6% (e-Diary data)
- 19.6% (All Data)
- Placebo: 9.1%
These results corresponded to odds ratios of 2.1 and 2.4, respectively, indicating a meaningful improvement compared to placebo. While the e-Diary-only analysis narrowly missed conventional statistical significance, the broader dataset achieved nominal significance.
Freedom from Most Bothersome Symptom
- Elismetrep 20 mg: 38.3%
- Placebo: 24.2%
- Odds Ratio: 1.9
This endpoint demonstrated statistically significant improvement, suggesting that elismetrep effectively addresses key migraine-associated symptoms beyond pain alone.
Pain Relief at 2 Hours
- Elismetrep 20 mg: 58.8%
- Placebo: 42.4%
- Odds Ratio: 1.9
The substantial improvement in pain relief further reinforces the therapeutic potential of elismetrep.
Safety and Tolerability Profile
One of the most encouraging aspects of the study was the favorable safety profile of elismetrep. No serious adverse events were reported across any dose group.
Adverse events were dose-dependent but generally mild to moderate in severity. At the highest dose (20 mg), the most commonly reported side effects included:
- Oral paresthesia (9.8%)
- Sensation of heat (9.8%)
- General paresthesia (7.8%)
- Hot flush (7.8%)
- Flushing (5.9%)
Importantly, these side effects were transient and manageable, suggesting that elismetrep is well tolerated even at higher doses.
Expert Insights
Leading migraine expert Peter J. Goadsby emphasized the significance of these findings, noting that migraine remains a highly disabling condition with substantial unmet medical needs. Many patients cycle through multiple therapies without achieving consistent relief, highlighting the limitations of current treatment options.
He pointed out that elismetrep’s novel mechanism could introduce an entirely new class of migraine therapies, potentially transforming treatment paradigms and offering hope to patients who have not benefited from existing medications.
Kallyope’s Chief Medical Officer, Brett Lauring, also underscored the importance of innovation in migraine care. With only about 30% of patients experiencing adequate relief from current treatments, the need for new approaches is critical. He expressed optimism that targeting a different pathway in the migraine cascade could lead to more effective and reliable outcomes.
Next Steps: Registrational Trials
Based on the positive Phase 2b results, Kallyope plans to initiate registrational trials in mid-2026. These studies will be crucial in confirming the efficacy and safety of elismetrep in larger patient populations and will serve as the foundation for potential regulatory approval.
The company believes that the current data strongly support advancing the program to this next stage of development.
Advancements in Drug Formulation
In addition to the clinical findings, Kallyope announced the development of a new liquid-filled softgel capsule (LSGC) formulation of elismetrep. This formulation offers significantly faster absorption compared to the version used in the Phase 2b study.
The improved pharmacokinetic profile is expected to result in:
- Faster onset of action
- Enhanced efficacy at the critical 2-hour evaluation point
This advancement could further strengthen the clinical performance of elismetrep in future trials and improve patient outcomes.
Full pharmacokinetic data for the new formulation are expected to be presented at an upcoming medical meeting later in 2026.
Broader Impact and Future Outlook
Migraine affects hundreds of millions of people worldwide and is a leading cause of disability. The introduction of a new class of therapies targeting TRPM8 channels could significantly expand the treatment landscape.
Elismetrep’s ability to deliver meaningful symptom relief, combined with its favorable safety profile, positions it as a strong candidate for addressing unmet needs in migraine care. If successful in registrational trials, it could provide a much-needed alternative for patients who do not respond to existing treatments.
Kallyope’s leadership emphasized their commitment to rapidly advancing this program, recognizing the profound impact that effective migraine therapies can have on patients’ quality of life.
The Phase 2b study results for elismetrep mark an important milestone in migraine research. By validating a novel mechanism of action and demonstrating promising efficacy and safety, Kallyope has taken a significant step toward potentially transforming migraine treatment.
With registrational trials on the horizon and ongoing improvements in drug formulation, elismetrep represents a compelling example of innovation in neuroscience and drug development. Its continued progress will be closely watched by clinicians, researchers, and patients alike, as the search for more effective migraine therapies continues.
About Elismetrep
Elismetrep (K-304) is an investigational, novel, oral, TRPM8 migraine-associated channel blocker (MACB) that is highly selective for TRPM8 migraine-associated channels versus other TRP channels. Specifically designed to block TRPM8 activity, elismetrep has been shown to reduce migraine pain and associated symptoms. The Phase 2b dose-ranging and proof of concept trial for elismetrep for the acute treatment of migraine in adults demonstrated clinically meaningful efficacy that is competitive with the current leading marketed therapies. Registrational trials for elismetrep for the acute treatment of migraine are planned to initiate by mid-2026. Elismetrep is an investigational product and has not been approved by the FDA or any other regulatory agency
Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic therapies for health challenges faced by hundreds of millions of people globally. Kallyope’s lead programs target previously unknown drivers of disease in neural signaling pathways. The Company’s most advanced candidate, elismetrep (K-304), is poised to begin registrational trials for the acute treatment of migraine in mid-2026. The metabolism pipeline includes agents that target a novel target identified and validated by the Company’s Klarity™ platform, as well as oral small molecule approaches to the highly validated amylin pathway for the treatment of obesity. Kallyope was founded by world-leading neuroscientists and continues to explore the role of neural circuits in driving disease.
